Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections

Medicine and Dentistry

• Experience 100%
• Drug 100%
• Gram-Negative Bacterial Infection 100%
• Therapeutic Procedure 60%
• Patient 60%
• Carbapenem 40%
• Threat 20%
• Pseudomonas aeruginosa 20%
• Exanthem 10%
• Mortality Rate 10%
• Recurrent Disease 10%
• Global Health 10%
• Organism 10%
• Prospective Study 10%
• Monotherapy 10%
• Retrospective Cohort Study 10%
• Physical Disease by Body Function 10%
• APACHE II 10%
• Multidrug-Resistant Gram-Negative Bacteria 10%
• Acinetobacter Baumannii 10%
• Survival 10%
• Cephalosporin 10%
• Adverse Drug Reaction 10%
• Siderophore 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug 100%
• Gram Negative Infection 100%
• Cefiderocol 100%
• Carbapenem 40%
• Pseudomonas aeruginosa 20%
• Organisms 10%
• Adverse Drug Reaction 10%
• Cohort Study 10%
• Prospective Study 10%
• Mortality Rate 10%
• Survival 10%
• Recurrent Disease 10%
• Physical Disease by Body Function 10%
• Rash 10%
• Multidrug-Resistant Gram-Negative Bacteria 10%
• Monotherapy 10%
• Acinetobacter Baumannii 10%
• Siderophore 10%
• Cephalosporin 10%